news archive

  INNform - Generics Industry News

Keep abreast of news headlines, mergers and acquisitions, press releases, court cases and expert opinions. Our news archive is fully searchable, containing articles since May '04.


  Generics Industry News Search news archive  
        Enter keyword :                  news archive
       
       
 
   news archive   Keep INNformed with the latest news
   news archive  Search our extensive news archive
   news archive  Access leading industry expert opinions
   news archive  View the latest DMFs
   news archive  Post your press releases and feedback
 
   July 2009 News Archive news archive  


01/07/2009  FDA clears Teva to sell generic oral contraceptive news archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of Ortho McNeil Janssen's oral contraceptive, Ortho Tri-Cyclen Lo. Shipment of this product, for which Teva's trade name is Tri-Lo Sprintec, has commenced. ...
      Read more >>
       
02/07/2009  Dr Reddy's Gets Tentative US OK For Generic Valtrex Tablets news archive
India's Dr. Reddy's Laboratories Ltd. has received tentative approval from the U.S. Food and Drug Administration to sell generic Valacyclovir hydrochloride tablets in two doses...
      Read more >>
       
02/07/2009  Sun Pharmaceutical Industries Ltd announces USFDA tentative approval for generic Optivar news archive
Sun Pharmaceutical Industries Ltd. announced receipt of a tentative approval from USFDA for Sun Pharma's Abbreviated New Drug Application for generic Optivar, Azelastine ophthalmic solution, 0.05%....
      Read more >>
       
02/07/2009  Prasco and Axcan Pharma Sign a Distribution and Supply Agreement for Authorized Generic Versions of URSO Forte Scored and URSO 250 news archive
Prasco Laboratories, a privately held pharmaceutical company located in Cincinnati, Ohio, announced today it has entered into a distribution and supply agreement with Axcan Pharma US, Inc. for Authorized Generic versions of URSO 250 and URSO Forte Scored (ursodiol tablets, USP) family of products...
      Read more >>
       
02/07/2009  GSK further extends its product portfolio in the Middle East and North Africa news archive
GlaxoSmithKline plc (GSK) today announced that it has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m. The business comprises a portfolio of 13 branded pharmaceuticals with annual sales in 2008 of $11.8m...
      Read more >>
       
03/07/2009  U.K. Issues Recall Of Various Generics news archive
Violations of European standards by an Indian contract manufacturer have prompted recalls of multiple generic drugs in the U.K....
      Read more >>
       
03/07/2009  U. Iowa sues drugmaker alleging patent infringement news archive
The University of Iowa is involved in a legal dispute with the makers of Humira, for allegedly intentionally violating two UI patented medical tools. ...
      Read more >>
       
06/07/2009  Takeda Sues Torrent to Stop Generic Copy of Actos Diabetes Pill news archive
Takeda Pharmaceutical Co. sued India's Torrent Pharmaceuticals Ltd. to prevent it from selling a copy of the Actos diabetes pill in the U.S. until 2016. ...
      Read more >>
       
07/07/2009  Teva Stops Shipping Generic Birth Control Pill news archive
Teva Pharmaceutical Industries Ltd. said Tuesday it stopped shipping a generic version of Johnson & Johnson's birth control pill Ortho Tri-Cyclen....
      Read more >>
       
07/07/2009  Apotex Goes to Court to Get Alzheimer's Drug OK news archive
Canada's Apotex Inc is asking a U.S. court to rule that it did not infringe Eisai Co's (4523.T) patents on Aricept, the world's No. 1 Alzheimer's disease treatment....
      Read more >>
       
07/07/2009  Sun Pharma Announces USFDA Approval For Generic Casodex Tablets news archive
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for an Abbreviated New Drug Application (ANDA) for generic Casodex, Bicalutamide tablets....
      Read more >>
       
08/07/2009  SUNY, NYU, Galderma Sue Indian Generics Pharma Lupin for Allegedly Infringing Rosacea Rx IP news archive
The State University of New York, New York University, and L'Oreal subsidiary Galderma Laboratories are suing Indian generic drugmaker Lupin for allegedly infringing four patents related to Oracea, Galderma's orally administered treatment for rosacea....
      Read more >>
       
08/07/2009  Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums news archive
Watson Pharmaceuticals, Inc., a leader in generic and specialty branded pharmaceuticals, today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration to market its over-the-counter Nicotine Polacrilex Gum USP, 2 mg and 4 mg strengths in the coated fruit and cinnamon flavors....
      Read more >>
       
10/07/2009  Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to Lexapro Patent Litigation news archive
Forest Laboratories, Inc. and its wholly-owned subsidiary, Forest Laboratories Holdings, Ltd., and H. Lundbeck A/S announced today that they have entered into a settlement agreement with Sun Pharmaceutical Industries Ltd. and Caraco Pharmaceutical Laboratories, Ltd., regarding pending patent infringement disputes regarding U.S. Patent Re. No. 34,712, U.S. Patent No. 6,916,941, and U.S. Patent No. 7,420,069, which were licensed to Forest by H. Lundbeck A/S on an exclusive basis in the United States. These patents are listed in the U.S. Food and Drug Administration's Orange Book for Forest's Lexapro brand escitalopram oxalate tablet products....
      Read more >>
       
10/07/2009  Watson Pharmaceuticals Resumes Shipment of INFeD - Iron Dextran Injection, USP news archive
Watson Pharmaceuticals, Inc. a leading specialty pharmaceutical company, announced today that it has resumed shipments to reintroduce its intravenous iron replacement therapy INFeD (iron dextran injection, USP)....
      Read more >>
       
10/07/2009  Glenmark to Launch Fosinopril Sodium and Hydrochlorothiazide Tablets in The US news archive
Glenmark Generics Inc., USA, the US subsidiary of Glenmark Generics Limited and a leading company in the manufacture, marketing and distribution of high-quality, low-cost generic pharmaceutical products in the US, initiated the launch of Fosinopril Sodium and Hydrochlorothiazide tablets in the U.S. market. ...
      Read more >>
       
11/07/2009  Aurobindo Pharma Receives Final Approval for Fosinopril Sodium and Hydrochlorothiazide Tablets news archive
Aurobindo Pharma Limited is pleased to announce that it has received final approval for Fosinopril Sodium and Hydrochlorothiazide Tablets USP 10/12.5mg and 20/12.5mg from the US Food & Drug Administration (USFDA). ...
      Read more >>
       
12/07/2009  Apotex Inc v. Glaxo Wellcome Inc. et al. news archive
Declaratory judgment of non-infringement of U.S. Patent Nos. 5,879,706 (Valaciclovir Tablets Containing Colloidal Silicon Dioxide) and 6,107,302 (Guanine Derivative) in conjunction with Apotex's filing of an ANDA to manufacture a generic version of GSK's Valtrex...
      Read more >>
       
13/07/2009  When Should Biotech Drugs Face Generic Competition? news archive
In the debate among lawmakers over generic biotech drugs, the disagreement comes down to this: How many years should makers of the brand-name biologics be protected from generic competition? ...
      Read more >>
       
13/07/2009  FDA approves Perrigo's generic nicotine lozenge news archive
Perrigo Co. said Monday it received FDA approval to market a generic version of GlaxoSmithKline PLC's Commit anti-smoking lozenge in cherry and cinnamon flavors...
      Read more >>
       
13/07/2009  US Senate Panel OKs 12-Year Biologic Drug Exclusivity news archive
The Senate Health, Education, Labor and Pensions Committee approved an amendment late Monday that would protect makers of biologic drugs from competition from generic drug manufacturers for 12 years...
      Read more >>
       
14/07/2009  Irinotecan Actavis Launched on Patent Expiry in 6 EU Countries news archive
Actavis today announced the launch of Irinotecan, a cancer drug, in the UK, France, Netherlands, Germany, Austria and Sweden on 13 and 14 July. The patents expired on 12 and 13 July, respectively. Actavis was first to market in all 6 countries....
      Read more >>
       
14/07/2009  Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR triptorelin pamoate NDA from US FDA news archive
Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, announced today that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for TRELSTAR 22.5 mg (triptorelin pamoate for injectable suspension), a 24-week formulation of TRELSTAR for the palliative treatment of advanced prostate cancer. The TRELSTAR NDA was prepared in cooperation with Debiopharm Group, a Swiss-based global biopharmaceutical group of companies....
      Read more >>
       
15/07/2009  Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR news archive
Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its trospium chloride extended-release 60 mg capsules prior to the expiration of a patent owned by Supernus Pharmaceuticals, Inc. Watson's trospium chloride extended-release capsules are the generic version of Allergan Inc.'s Sanctura XR product, which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency....
      Read more >>
       
16/07/2009  Generic Diprivan Recall: Teva Propofol Contaminated and Linked to Illnesses news archive
More than 57,000 vials of the anesthetic propofol, a generic version of Diprivan, have been recalled after testing confirmed that two lots of the medication manufactured by Teva Pharmaceuticals may be tainted...
      Read more >>
       
16/07/2009  Roche set to move SC against high court ruling on Tarceva news archive
Basel-based drug maker Hoffman-La Roche Ltd plans to drag Cipla Ltd to the Supreme Court, challenging an April ruling of Delhi high court that dismissed Roche's appeal on a patent infringement case....
      Read more >>
       
16/07/2009  Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel news archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg (base)....
      Read more >>
       
16/07/2009  FDA Accepts Tris Pharma's ANDA with Paragraph IV certification for a generic equivalent to Delsym news archive
Tris Pharma, Inc., a drug delivery and specialty pharmaceutical company, today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 12-hour sustained release Dextromethorphan liquid suspension product prior to the expiration of a patent listed in the FDA's orange book for Reckitt Benckiser's Delsym product. Deslym, a leading OTC brand and the only FDA approved 12-hour liquid product for cough is different from most brands of cough medicine as the active ingredient is "time released" in liquid syrup...
      Read more >>
       
17/07/2009  Teva Provides Update On Generic Ortho Tri-Cyclen Lo news archive
Teva Pharmaceutical Industries Ltd. announced today that further to its press release dated July 7, 2009, the Company and Ortho McNeil Janssen have extended their agreement to cease shipments of generic versions of Ortho Tri-Cyclen Lo, until the earlier of (a) the Court's ruling on the motion for preliminary injunction or (b) July 29....
      Read more >>
       
20/07/2009  Pharma Israel backs appeal of drug patent case news archive
Pharma Israel, which represents international pharmaceutical companies in Israel, has asked for "friend of the court" standing in the petition to the Supreme Court filed by Danish company H. Lundbeck A/S against the Manufacturers Association of Israel and generic drug maker Unipharm Ltd....
      Read more >>
       
20/07/2009  European Comission's Competition Inquiry into the Pharmaceutical Sector news archive
The investigation into the anti-competitive conditions in the pharmaceutical sector was begun by the European Union Commission on January 15, 2008. The Preliminary Report was released in December 2008 (Refer to previous post titled "Prelim report points to anti-competitive practices in EU's Pharma industry"). The investigation; "Pharmaceutical Sector Inquiry" launched by the Commission under Article 17 of Regulation 1/2003 (of 16 December 2002) on the implementation of the rules on Competition laid down in Articles 81 and 82 of the Treaty...
      Read more >>
       
20/07/2009  Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol news archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product....
      Read more >>
       
20/07/2009  Ranbaxy Receives Final Approval To Manufacture And Market Ran-Amlodipine Tablets In Canada news archive
Ranbaxy Laboratories Limited (RLL), announced today that the Company has received final approval in Canada to manufacture and market Ran-Amlodipine Tablets, 5 and 10 mg (Amlodipine Besylate Tablets) from Health Canada, Therapeutic Products Directorate (TPD). Total generic market size of Amlodipine Besylate Tablets in Canada is $456 million ($CAD) [IMS-CDH: May 2009)]. Ran-Amlodipine Tablets are indicated and employed as an antihypertensive-antianginal agent....
      Read more >>
       
21/07/2009  Ranbaxy Receives Final Approval to Manufacture and Market Ran-Simvastatin Tablets in Canada news archive
Ranbaxy Pharmaceuticals Canada Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced today that RLL has received approval in Canada to manufacture and market Ran-Simvastatin 5 mg, 10 mg, 20 mg, 40 mg and 80 mg tablets (Simvastatin) from Health Canada, Therapeutic Products Directorate ...
      Read more >>
       
21/07/2009  Synthon announces European approvals for generic Rivastigmine news archive
Synthon is announcing that it has successfully completed multiple decentralized procedures (DCP) for Rivastigmine. Regulatory clearance has been obtained for Synthon's product in nearly all European countries. Registration has been obtained for multiple dosage forms including capsules (1.5, 3, 4.5 and 6 mg) and an oral solution (2 mg/ml)...
      Read more >>
       
22/07/2009  New! Co Ropinirole tablets news archive
Cobalt Pharmaceuticals Inc. is pleased to introduce the newest product in our portfolio CO Ropinirole tablet, the cost effective alternative to ReQuip. ...
      Read more >>
       
23/07/2009  Ranbaxy Non-Sterile Drug Plant At Dewas Receives GMP Compliance Approval From MHLW-Japan news archive
Ranbaxy Laboratories Limited (Ranbaxy) announced today that the Ministry of Health and Labour Welfare (MHLW-Japan), have issued a Good Manufacturing Practice (GMP) certificate for its non-sterile manufacturing site located at Dewas (India). The MHLW approval has been granted for a period of 5 years and will cover all products that are currently manufactured at this site and that will be filed in the future for Japan....
      Read more >>
       
23/07/2009  Teva, Taro Lobby US Legislators on Biogenerics news archive
The struggle over US biogenerics legislation is continuing. Generic drug companies are now reacting to the vote by the Senate Committee on Health, Education, Labor and Pensions, which was unfavorable to biogenerics. ...
      Read more >>
       
24/07/2009  Teva and Ortho-McNeil-Janssen Settle Ortho Tri-Cyclen Lo Litigation news archive
Teva Pharmaceutical Industries Ltd. announced today that it has entered into a definitive agreement with Ortho-McNeil-Janssen to settle the patent infringement lawsuit in the U.S. District Court for the District of New Jersey related to Teva's generic version of the oral contraceptive, Ortho Tri-Cyclen Lo...
      Read more >>
       
27/07/2009  Taro Receives FDA Approval for Cetirizine Hydrochloride Tablets ANDA news archive
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for cetirizine hydrochloride tablets (OTC), 5 mg and 10 mg. The product will be marketed by Taro's U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc. ...
      Read more >>
       
27/07/2009  Taro Sues Synerx Pharma, Karalex Pharma and DPT Laboratories for Patent Infringement news archive
Taro Pharmaceutical Industries Ltd. said today that it has filed a lawsuit against Synerx Pharma, LLC, DPT Laboratories, Ltd. and Karalex Pharma, LLC (a subsidiary of Eagle Pharmaceuticals, Inc.) in the United States District Court for New Jersey for infringement of its United States Patent No. 7,560,445 covering its Ovide(r) (malathion) Lotion, 0.5%. ...
      Read more >>
       
27/07/2009  "In Transit" Drug Seizures and TRIPS: UK Decision May Help Indian Companies news archive
The IPKat reports a very recent decision from the UK courts involving an attempted seizure of "in transit" goods. The brief facts are as below:...
      Read more >>
       
27/07/2009  Court Upholds Data Exclusivity Rules For Pharmaceutical Manufacturers news archive
The Federal Court, in a decision released on July 17, 2009, has upheld Canada's Food and Drug Regulations as they relate to the protection of data that is submitted by innovators for the purpose of obtaining regulatory approval ...
      Read more >>
       
28/07/2009  Mylan Reports That the FDA Determined That All Accusations Were Unfounded news archive
Mylan Inc. today reported that in addition to the press release it issued on Sunday, the company proactively and as a courtesy had contacted the U.S. Food and Drug Administration (FDA) over the weekend to bring to its attention a recent news article. As a result, the FDA visited the company's Morgantown, W.VA., manufacturing facility Monday morning and has determined that the baseless accusations in the article were unfounded. The FDA noted there was no evidence of any data deletion. All data was reviewed and was present and accounted for; the Agency agreed that this was a minor Standard Operating Procedures (SOP) deviation that existed, was fully investigated, and all corrective actions were fully implemented by Mylan....
      Read more >>
       
28/07/2009  Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit news archive
Watson Pharmaceuticals, Inc. a leader in generic and specialty branded pharmaceuticals, today announced a license agreement with GeneraMedix, Inc., for the exclusive US marketing rights to a generic version of Ferrlecit (sodium ferric gluconate complex in sucrose injection), a drug indicated for the treatment of iron deficiency anemia in hemodialysis patients receiving supplemental epoetin therapy....
      Read more >>
       
28/07/2009  Apotex Asks US Supreme Court To Overturn Plavix Patent news archive
Generic-drug manufacturer Apotex Inc. has asked the U.S. Supreme Court to overturn a lower court ruling that upheld the patent for Plavix, the blockbuster anti-clotting drug co-marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis....
      Read more >>
       
29/07/2009  Judge Restarts Litigation Over Cephalon's Patent Deals news archive
A U.S. judge essentially restarted litigation in which the Federal Trade Commission is trying to clear the way for generic competition for drug maker Cephalon Inc.'s top-selling product...
      Read more >>
       
29/07/2009  Ranbaxy Gains Approval To Market Ran-Ropinirole Tablets in Canada news archive
Ranbaxy Pharmaceuticals Canada Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced today that RLL has received approval in Canada to manufacture and market Ran-Ropinirole 0.25 mg, 1.0 mg, 2.0 mg, and 5.0 mg tablets (Ropinirole Hydrochloride) from Health Canada, Therapeutic Products Directorate...
      Read more >>
       
29/07/2009  The Next Generation Generic Pharmaceutical Company news archive
Robert Wessman and Alvogen Group combine to build a leading international generics company. Robert Wessman, former CEO of Actavis, one of the world's leading generic pharmaceutical companies, has become Executive Chairman and a major shareholder in the company...
      Read more >>
       
29/07/2009  Teva Fights for Biotech Generics news archive
If the U.S. wants to lower its annual bill for pharmaceuticals, there's a plausible way to do it: Permit drugmakers to crank out generic biotech products. Right now, the U.S. Food & Drug Administration has no mechanism for reviewing or approving these complex medicines...
      Read more >>
       
30/07/2009  Pharmaceutical Patent Settlements Under Fire On Both Sides Of The Atlantic news archive
In recent weeks, the pharmaceutical industry has been in the crosshairs of antitrust enforcers in the U.S. and in Europe. Specifically, patent litigation settlements in which a brand pharmaceutical manufacturer makes a payment to a potential generic entrant in return for a delay of entry (so-called reverse payment settlements) are under attack on both sides of the Atlantic. ...
      Read more >>
       
30/07/2009  Dr. Reddy's Launches Execare in India news archive
Dr. Reddy's Laboratories Ltd. has launched Execar (Halometasone Cream 0.05%) in India. Used in the treatment of acute/chronic eczema & vitiligo, Execar is a potent steroid and is recommended as an alternative to Betamethasone Dipropionate and Mometasone furoate. ...
      Read more >>
       
31/07/2009  U.S. House Panel Backs 12-year Biotech Drug Shelter news archive
Biotech drugs would be protected from competition from cheaper rivals for 12 years under a proposal adopted by a key House committee on Friday....
      Read more >>
       
31/07/2009  Glenmark Generics Receives ANDA Approval from the US FDA for Alclometasone Dipropionate Ointment news archive
Glenmark Generics Limited has received ANDA approval from the United States Food and Drug Administration (U.S. FDA) for Alclometasone Dipropionate Ointment, 0.05% and will commence marketing and distribution of this product in the market immediately. In June'09, Glenmark received FDA approval for Alclometasone Dipropionate cream....
      Read more >>
       

             Contribute

If you would like to contribute or publish your company press releases at GenericsWeb, please email us.

Contact Us | Terms and Conditions | Privacy Policy | Copyright GenericsWeb 2007